fda compounding semaglutide enforcement news november 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA Warns on Certain Forms

So I know there were many different ways you could have protected or extended the half-life one way or another, but this seemed to be a breakthrough of many along the chain of breakthroughs

GLP-1 Therapies and Risk of Muscle Loss Glucagon-like peptide-1 (GLP-1) medications have increasingly been prescribed to treat cardiometabolic conditions such as obesity, diabetes, and cardiovascular diseasesYeo et al (2024) conducted a nationwide analysis on the usage of GLP-1's in patients without diabetes and observed a 700% (from 21,000 in 2019 to 174,000 in 2023) increase between the years 2019-2023

Orlistat Viewed as effective for modest weight loss (5- 10% ), but its efficacy is highly dependent on patient adherence to a low-fat diet

More importantly, the weight loss caused by tirzepatide in these animals likely contributed to adverse outcomes independently of the drug itself

Oral tirzepatide Oral tirzepatide is in advanced development and early data suggests it may achieve weight loss results closer to injectable tirzepatide than oral semaglutide achieves relative to its injectable counterpart

Alicia Lundby, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark